Artiva Biotherapeutics, Inc. Common Stock (ARTV)
9.97
(-9.69%)
9.97
(-9.69%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -47.43 Million | -50.82 Million | -15.3 Million | -13.54 Million |
| Net Income | -28.72 Million | -58.78 Million | -71.82 Million | -17.99 Million |
| Depreciation & Amortization | 2.26 Million | 1.15 Million | 248 Thousand | 73 Thousand |
| Deferred income taxes | - | - | - | - |
| Stock-based compensation | 7.05 Million | 6.58 Million | 4.3 Million | 297 Thousand |
| Change in working capital | -28.28 Million | -3.86 Million | 33.41 Million | 4.35 Million |
| Other non-cash items | 251 Thousand | - | 18.55 Million | -278 Thousand |
| Investing Cash Flow | -25.97 Million | -6.29 Million | -1.72 Million | -284 Thousand |
| Investments in PPE | -3.25 Million | -6.29 Million | -1.72 Million | -284 Thousand |
| Acquisitions | - | - | - | - |
| Investment purchases | -49.51 Million | - | - | - |
| Sales/Maturities of investments | 26.8 Million | - | - | - |
| Other Investing Activities | - | - | - | - |
| Financing Cash Flow | 24.39 Million | -1.26 Million | 152.75 Million | 37.39 Million |
| Debt repayment | - | - | - | -3 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | -12 Thousand | -5000.00 | - | - |
| Common Stock Issuance | - | - | - | 215 Thousand |
| Other Financing Activities | 24.4 Million | -1.59 Million | -2.03 Million | -459 Thousand |
| Accounts receivables | -510 Thousand | -57 Thousand | -468 Thousand | - |
| Accounts payables | -408 Thousand | 190 Thousand | -1.24 Million | 1.82 Million |
| Inventory | - | - | - | - |
| Other working capital | -26.38 Million | -2.38 Million | 28.92 Million | 249 Thousand |
| Cash at beginning of period | 102.77 Million | 161.16 Million | 25.44 Million | 1.87 Million |
| Cash at end of period | 53.76 Million | 102.77 Million | 161.16 Million | 25.44 Million |
| Capital Expenditure | -3.25 Million | -6.29 Million | -1.72 Million | -284 Thousand |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | -49.01 Million | -58.39 Million | 135.72 Million | 23.57 Million |
| Free Cash Flow | -50.68 Million | -57.12 Million | -17.02 Million | -13.82 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -17.84 Million | -13.96 Million | -28.72 Million | -11.28 Million | -16.71 Million | -58.78 Million |
| Depreciation & Amortization | 603 Thousand | 587 Thousand | 2.26 Million | 538 Thousand | 578 Thousand | 1.15 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.48 Million | 1.4 Million | 7.05 Million | 2.45 Million | 1.83 Million | 6.58 Million |
| Change in working capital | -7000.00 | -3.01 Million | -28.28 Million | -3.46 Million | 64 Thousand | -3.86 Million |
| Other non-cash items | 2.07 Million | - | - | - | - | - |
| Investing Cash Flow | 1.34 Million | 9.78 Million | -25.97 Million | -20.95 Million | -1.86 Million | -6.29 Million |
| Investments in PPE | -464 Thousand | -18 Thousand | -3.25 Million | -581 Thousand | -1.86 Million | -6.29 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -12.18 Million | -6.2 Million | -49.51 Million | -22.37 Million | - | - |
| Sales/Maturities of investments | 14 Million | 16 Million | 26.8 Million | 2 Million | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -1.61 Million | - | 24.39 Million | 10 Thousand | -12 Thousand | -1.26 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -12 Thousand | - | -12 Thousand | -5000.00 |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -1.61 Million | - | - | - | - | -1.59 Million |
| Accounts receivables | 250 Thousand | 215 Thousand | -510 Thousand | -1.14 Million | -548 Thousand | -57 Thousand |
| Accounts payables | -954 Thousand | 851 Thousand | -408 Thousand | -592 Thousand | 520 Thousand | 190 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 85 Thousand | 45 Thousand | -26.38 Million | -1.78 Million | 388 Thousand | -2.38 Million |
| Cash at beginning of period | 48.45 Million | 53.76 Million | 102.77 Million | 86.66 Million | 102.77 Million | 161.16 Million |
| Cash at end of period | 34.5 Million | 48.45 Million | 53.76 Million | 53.95 Million | 86.66 Million | 102.77 Million |
| Capital Expenditure | -464 Thousand | -18 Thousand | -3.25 Million | -581 Thousand | -1.86 Million | -6.29 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -13.95 Million | -5.3 Million | -49.01 Million | -32.7 Million | -16.11 Million | -58.39 Million |
| Free Cash Flow | -14.14 Million | -15.1 Million | -50.68 Million | -12.34 Million | -16.1 Million | -57.12 Million |
SGP
CGIP
9668
NVX
9253
5JK